iBio, Inc. (NYSE:IBIO) , a major AI-driven innovator of precision antibody immunotherapies, has recently made significant appointments to strengthen its leadership team. The company announced the permanent appointments of Dr. Martin Brenner as Chief Executive Officer (CEO) and Felipe Duran as Chief Financial Officer (CFO), effective immediately. Dr. Brenner will continue to serve as iBio’s Chief Scientific Officer (CSO), a role he has held since December 2020.
These appointments come after Dr. Brenner and Mr. Duran served as interim CEO and CFO, respectively, earlier in 2023. Their successful performance in these roles led to the board’s decision to make their positions permanent. The board has expressed its confidence in Dr. Brenner and Mr. Duran to lead the company through its next phase of growth.
Chip Clark, Chairman of iBio’s Board, commended Dr. Brenner and Mr. Duran, stating that they have overseen developments that have advanced iBio’s AI-powered biotech strategy. These developments include the discovery of bispecific immuno-oncology therapies and the expansion of the company’s tech stack with the launch of EngageTx™. Clark further emphasized that Dr. Brenner and Mr. Duran are the right individuals to lead iBio as it enters an exciting new phase of growth.
Dr. Brenner brings a wealth of experience in drug discovery and development from his tenure at several renowned pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. He most recently served as the CSO at Pfenex Inc., where he played a pivotal role in the creation of an advanced pipeline of therapeutic equivalents, vaccines, biologics, and biosimilars using the patented Pfenex Expression Technology® platform. Pfenex Inc. was acquired in October 2020 by Ligand Pharmaceuticals Incorporated for a total value of up to $516 million. Before that, Dr. Brenner held leadership positions at Recursion Pharmaceuticals, Inc., and Stoke Therapeutics, Inc., where he contributed to cutting-edge research and development efforts. He holds a DVM from the Ludwig Maximilian University of Munich and a Ph.D. in Pharmacology from the Veterinary School of Hannover in Germany. Dr. Brenner has been recognized with prestigious awards for his contributions to scientific research.
Mr. Duran, before he was appointed iBio’s CFO, served as the company’s Vice President of Financial Planning and Analysis (FP&A) from April 2021 to February 2023. In this role, he played a strategic part in the company’s forecasting, business planning, management reporting, and business analytics activities. Previously, Mr. Duran held executive positions at Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, one of the largest generic pharmaceutical companies in the United States. During his tenure at Lupin, he made significant contributions to the company’s financial success and implemented effective pricing strategies that resulted in substantial regional sales growth. Mr. Duran’s experience includes key roles at Teva Pharmaceuticals and finance positions at Bupa and Noven Pharmaceuticals. He holds a B.A. in Finance and an MBA from the University of Miami.
iBio, Inc. is a biopharmaceutical company focused on developing next-generation biopharmaceuticals using computational biology and 3D modeling of subdominant and conformational epitopes. By leveraging AI technology, iBio aims to discover new antibody treatments for challenging-to-target cancers and other diseases.
With the permanent appointments of Dr. Brenner and Mr. Duran, iBio has solidified its leadership team and is well-positioned for future growth. The combined expertise and experience of these individuals, along with the company’s commitment to innovation and AI-driven approaches, provide a strong foundation for iBio to continue making strides in the field of precision antibody immunotherapies.
Image provided by Lakewalktx.com